AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation

RecruitingNAAges 65 Years - anyAllSeoul National University Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aimed to compare the clinical outcomes of left bundle branch area pacing combined with atrioventricular node ablation and pharmacologic treatment optimized according to guidelines in patients with symptomatic atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion: Patients who meet all of the following inclusion criteria 1)-6). 1. Permanent atrial fibrillation 2. Age โ‰ฅ 65 years 3. Refractory or intolerant to antiarrhythmic drugs, rate control medications, or catheter ablation 4. New York Heart Association (NYHA) functional class II- IV 5. LVEF \> 40% (within the past 3 months) 6. Patients with at least one of the following: 1. HF hospitalization (defined as HF as the major reason for hospitalization or treatment for HF lasting โ‰ฅ12 hours and including treatment with intravenous (IV) diuretics at a healthcare facility) within 12 months 2. Elevated NT-proBNP (\>900 pg/ml) in the 30 days prior to enrollment Exclusion: Patients who meet at least one of the following exclusion criteria 1)-11). 1. Asymptomatic atrial fibrillation 2. Life expectancy to \< 12 months. 3. Primary moderate to severe valvular disease (except for functional mitral valve regurgitation or tricuspid valve regurgitation) 4. Mechanical tricuspid valve replacement 5. Severe chronic kidney disease (estimated Glomerular Filtration Rate โ‰ค 15 ml/1,73 m2 or receiving renal replacement treatment including hemodialysis or peritoneal dialysis) 6. Obstructive hypertrophic cardiomyopathy 7. Infiltrative cardiomyopathy (amyloidosis, sarcoidosis, Fabry disease, others) 8. Acute coronary syndrome or coronary revascularization (CABG or PCI) \<3 months 9. Severe primary pulmonary disease such as cor pulmonale, irreversible lung disease requiring inhalers, oxygen supplementation 10. Pacemaker/ICD/CRT treatment ongoing, or current pacemaker indication 11. Simultaneous participation in a different randomized clinical trial
๐Ÿ’Š

What it tests

  • Pacemaker implantation with Left bundle branch area pacing (LBBAP)
  • Atrioventricular node ablation (AVNA)
  • Pharmacologic therapy optimized for Atrial Fibrillation management
๐Ÿ“

Where

1 site
Seoul National University Hospital
Seoul, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy